The Parker Institute for Cancer Immunotherapy (PICI) collaborates with the Cancer Research Institute (CRI) on two key initiatives:

  • Tumor Neoantigen Selection Alliance (TESLA), through which CRI and PICI along with 30 of the world's leading cancer neoantigen research groups from academia and industry, aim to identify new molecular targets that may lead to next-generation, personalized immunotherapies. (Press release)
  • A multi-year clinical research collaboration with CRI and Bristol-Myers Squibb designed to accelerate immuno-oncology clinical studies across the CRI and PICI networks. (Press release)

*Immunotherapy results may vary from patient to patient.